Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered answering member label
tabling member	label

Search

1466560

registered interest
date	26/05/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines for Human Use (Clinical Trials) Regulations 2004
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans they have to amend the definition of the “Declaration of Helsinki” in Schedule 1 to the Medicines for Human Use (Clinical Trials) Regulations 2004 to refer to the current version of that Declaration.
tabling member printed	Baroness Finlay of Llandaff
uin	HL579
answer	answer is ministerial correction date of answer 10/06/2022 answer text <p>The Medicines and Healthcare products Regulatory Agency recently undertook a consultation on changes to the Medicines for Human Use (Clinical Trials) Regulations 2004, including Schedule 1. The responses to the consultation are currently being analysed and the response will be published in due course.</p> answering member printed Lord Kamall question first answered 10/06/2022 11:31:40 answering member 4909 label Biography information for Lord Kamall
tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1171817

registered interest
date	20/01/2020
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Lord Duncan of Springbank on 28 October 2019 (HL48), whether the decision to classify the default rate of loans made by the British Business Bank via peer-to-peer platforms as commercially sensitive information was to protect (1) the British Business Bank, or (2) the identify of borrowers; and if it was to protect the identity of borrowers, whether they will publish the aggregate value of (a) defaulted, and (b) provisional, loans through peer-to-peer platforms for each of the last three financial years.
tabling member printed	Lord Myners
uin	HL579
answer	answer is ministerial correction date of answer 28/01/2020 answer text <p>Data provided to the British Business Bank (BBB) by its delivery partners to meet portfolio monitoring and reporting requirements remains commercially sensitive to the delivery partners and as such is governed by confidentiality agreements. An individual delivery partner may choose to publish data on the overall performance of their loan book, which may include but will not be limited to BBB backed investments. A list of BBB’s delivery partners can be found on their website.</p><p> </p><p>The BBB’s Annual Report and Accounts (“Enabling Small Businesses to Grow and Prosper”) includes information on the BBB’s overall performance and is available on the website</p> answering member printed Lord Duncan of Springbank question first answered 28/01/2020 15:47:32 answering member 4686 label Biography information for Lord Duncan of Springbank
tabling member	3869 label Biography information for Lord Myners